Epsilon aminocaproic acid prevents bleeding in severely thrombocytopenic patients with hematological malignancies. (åbner nyt vindue)

Antun AG, Gleason S, Arellano M, Langston AA, McLemore ML, Gaddh M, el Rassi F, Bernal-Mizrachi L, Galipeau J, Heffner LT Jr, Winton EF, Khoury HJ.

Kilde‎: Cancer 2013;119(21):3784-7.

Indekseret‎: PubMed 23921838

DOI‎: 10.1002/cncr.28253

https://www.ncbi.nlm.nih.gov/pubmed/23921838 (åbner nyt vindue)

Tranexamic acid for control of haemorrhage in acute promyelocytic leukaemia. (åbner nyt vindue)

Avvisati G, ten Cate JW, Büller HR, Mandelli F.

Kilde‎: Lancet 1989;334(8655):122-4.

Indekseret‎: PubMed 2567893

https://www.ncbi.nlm.nih.gov/pubmed/2567893 (åbner nyt vindue)

Tranexamic acid therapy in acute myeloid leukemia: possible reduction of platelet transfusions. (åbner nyt vindue)

Ben-Bassat I, Douer D, Ramot B.

Kilde‎: Eur J Haematol 1990;45(2):86-9.

Indekseret‎: PubMed 2209824

https://www.ncbi.nlm.nih.gov/pubmed/2209824 (åbner nyt vindue)

Fibrinolytic inhibitors for cancer-associated bleeding problems. (åbner nyt vindue)

Dean A, Tuffin P.

Kilde‎: J Pain Symptom Manage 1997;13(1):20-4.

Indekseret‎: PubMed 9029858

https://www.ncbi.nlm.nih.gov/pubmed/9029858 (åbner nyt vindue)

Autologous stem-cell transplantation without hematopoietic support for the treatment of hematologic malignancies in Jehovah's Witnesses. (åbner nyt vindue)

Ford PA, Grant SJ, Mick R, Keck G.

Kilde‎: J Clin Oncol 2015;33(15):1674-9.

Indekseret‎: PubMed 25870085

DOI‎: 10.1200/JCO.2014.57.9912

https://www.ncbi.nlm.nih.gov/pubmed/25870085 (åbner nyt vindue)

Anti-fibrinolytic therapy with aminocaproic acid for the control of bleeding in thrombocytopenic patients. (åbner nyt vindue)

Garewal HS, Durie BG.

Kilde‎: Scand J Haematol 1985;35(5):497-500.

Indekseret‎: PubMed 4089529

https://www.ncbi.nlm.nih.gov/pubmed/4089529 (åbner nyt vindue)

Epsilon aminocaproic acid reduces transfusion requirements in patients with thrombocytopenic hemorrhage. (åbner nyt vindue)

Kalmadi S, Tiu R, Lowe C, Jin T, Kalaycio M.

Kilde‎: Cancer 2006;107(1):136-40.

Indekseret‎: PubMed 16708357

DOI‎: 10.1002/cncr.21958

https://www.ncbi.nlm.nih.gov/pubmed/16708357 (åbner nyt vindue)

Aminocaproic acid use in hospitalized patients with hematological malignancy: a case series. (åbner nyt vindue)

Marshall A, Li A, Drucker A, Dzik W.

Kilde‎: Hematol Oncol 2016;34(3):147-53.

Indekseret‎: PubMed 25641349

DOI‎: 10.1002/hon.2189

https://www.ncbi.nlm.nih.gov/pubmed/25641349 (åbner nyt vindue)

Tranexamic acid to treat life-threatening hemorrhage in prostate cancer associated disseminated intravascular coagulation with excessive fibrinolysis. (åbner nyt vindue)

Prokopchuk-Gauk O, Brose K.

Kilde‎: Cureus 2015;7(12):e428.

Indekseret‎: PubMed 26848417

DOI‎: 10.7759/cureus.428

https://www.ncbi.nlm.nih.gov/pubmed/26848417 (åbner nyt vindue)

A controlled trial of tranexamic acid therapy for the reduction of bleeding during treatment of acute myeloid leukemia. (åbner nyt vindue)

Shpilberg O, Blumenthal R, Sofer O, Katz Y, Chetrit A, Ramot B, Eldor A, Ben-Bassat I.

Kilde‎: Leuk Lymphoma 1995;19(1-2):141-4.

Indekseret‎: PubMed 8574160

DOI‎: 10.3109/10428199509059668

https://www.ncbi.nlm.nih.gov/pubmed/8574160 (åbner nyt vindue)

Acute promyelocytic leukaemia and acquired alpha-2-plasmin inhibitor deficiency: a retrospective look at the use of epsilon-aminocaproic acid (Amicar) in 30 patients. (åbner nyt vindue)

Wassenaar T, Black J, Kahl B, Schwartz B, Longo W, Mosher D, Williams E.

Kilde‎: Hematol Oncol 2008;26(4):241-6.

Indekseret‎: PubMed 18613223

DOI‎: 10.1002/hon.867

https://www.ncbi.nlm.nih.gov/pubmed/18613223 (åbner nyt vindue)

Use of Novoseven for arsenic trioxide-induced bleeding in PML. (åbner nyt vindue)

Alimoghaddam K, Ghavamzadeh A, Jahani M.

Kilde‎: Am J Hematol 2006;81(9):720.

Indekseret‎: PubMed 16804937

DOI‎: 10.1002/ajh.20713

https://www.ncbi.nlm.nih.gov/pubmed/16804937 (åbner nyt vindue)

Control of bleeding caused by thrombocytopenia associated with hematologic malignancy: an audit of the clinical use of recombinant activated Factor VII. (åbner nyt vindue)

Brenner B, Hoffman R, Balashov D, Shutluko E, Čulić SD, Nizamoutdinova E.

Kilde‎: Clin Appl Thromb Hemost 2005;11(4):401-10.

Indekseret‎: PubMed 16244765

https://www.ncbi.nlm.nih.gov/pubmed/16244765 (åbner nyt vindue)

The off-label use of recombinant FVIIa in the treatment of a patient with T-cell non-Hodgkin lymphoma who developed intra-abdominal and intra-pleural hemorrhages followed by high-dose methotreaxate therapy. (åbner nyt vindue)

Erduran E, Bahadir A, Mutlu M.

Kilde‎: Eur J Clin Med Oncol 2011;3(5):1-4.

Indekseret‎: EMBASE 2012295551

https://www.worldcat.org/title/european-journal-of-clinical-medical-oncology/oclc/645421559&referer=brief_results (åbner nyt vindue)

The potential role of recombinant activated FVII in the management of critical hemato-oncological bleeding: a systematic review. (åbner nyt vindue)

Franchini M, Veneri D, Lippi G.

Kilde‎: Bone Marrow Transplant 2007;39(12):729-35.

Indekseret‎: PubMed 17417659

DOI‎: 10.1038/sj.bmt.1705670

https://www.ncbi.nlm.nih.gov/pubmed/17417659 (åbner nyt vindue)

Effective hemostasis with rFVIIa treatment in two patients with severe thrombocytopenia and life-threatening hemorrhage. (åbner nyt vindue)

Gerotziafas GT, Zervas C, Gavrielidis G, Tokmaktsis A, Hatjiharissi E, Papaioannou M, Lazaridou A, Constantinou N, Samama MM, Christakis J.

Kilde‎: Am J Hematol 2002;69(3):219-22.

Indekseret‎: PubMed 11891811

https://www.ncbi.nlm.nih.gov/pubmed/11891811 (åbner nyt vindue)

Use of recombinant activated factor VII in a Jehovah's Witness patient. (åbner nyt vindue)

Hsieh A, Cheong I.

Kilde‎: Am J Emerg Med 2007;25(9):1085.e1-2.

Indekseret‎: PubMed 18022514

DOI‎: 10.1016/j.ajem.2007.03.007

https://www.ncbi.nlm.nih.gov/pubmed/18022514 (åbner nyt vindue)

Clinical experience with recombinant factor VIIa in patients with thrombocytopenia. (åbner nyt vindue)

Kristensen J, Killander A, Hippe E, Helleberg C, Ellegard J, Holm M, Kutti J, Mellqvist UH, Johansson JE, Glazer S, Hedner U.

Kilde‎: Haemostasis 1996;26 Suppl 1:159-64.

Indekseret‎: PubMed 8904193

https://www.ncbi.nlm.nih.gov/pubmed/8904193 (åbner nyt vindue)

Successful treatment of severe gastrointestinal bleeding after chemotherapy in acute myeloblastic leukemia with recombinant activated factor VII: report on one case and review of other uses in acute leukemias. (åbner nyt vindue)

Pamuk GE, Taşçi M, Oztürk E, Demir M.

Kilde‎: Med Oncol 2010;27(1):16-9.

Indekseret‎: PubMed 19137431

DOI‎: 10.1007/s12032-008-9163-y

https://www.ncbi.nlm.nih.gov/pubmed/19137431 (åbner nyt vindue)

Recombinant factor VIIa for bleeding in refractory thrombocytopenia. (åbner nyt vindue)

Vidarsson B, Önundarson PT.

Kilde‎: Thromb Haemost 2000;83(4):634-5.

Indekseret‎: PubMed 10780334

https://www.ncbi.nlm.nih.gov/pubmed/10780334 (åbner nyt vindue)

Effective treatment of life-threatening bleeding with recombinant activated factor VII in a patient with acute promyelocytic leukaemia. (åbner nyt vindue)

Zver S, Andoljšek D, Černelč P.

Kilde‎: Eur J Haematol 2004;72(6):455-6.

Indekseret‎: PubMed 15128428

DOI‎: 10.1111/j.1600-0609.2004.00237.x

https://www.ncbi.nlm.nih.gov/pubmed/15128428 (åbner nyt vindue)

Management of bleeding complications of hematologic malignancies. (åbner nyt vindue)

Green D.

Kilde‎: Semin Thromb Hemost 2007;33(4):427-34.

Indekseret‎: PubMed 17525900

DOI‎: 10.1055/s-2007-976178

https://www.ncbi.nlm.nih.gov/pubmed/17525900 (åbner nyt vindue)

Vitamin K deficiency in cancer patients referred to a hospital palliative care team with bleeding and the impact of vitamin K replacement on laboratory indicators of vitamin K status. (åbner nyt vindue)

Harrington DJ, Booth L, Dando N, Cottingham L, Beynon T.

Kilde‎: Int J Lab Hematol 2013;35(4):457-9.

Indekseret‎: PubMed 23216984

DOI‎: 10.1111/ijlh.12035

https://www.ncbi.nlm.nih.gov/pubmed/23216984 (åbner nyt vindue)

Management of bleeding in patients with advanced cancer. (åbner nyt vindue)

Pereira J, Phan T.

Kilde‎: Oncologist 2004;9(5):561-70.

Indekseret‎: PubMed 15477642

DOI‎: 10.1634/theoncologist.9-5-561

https://www.ncbi.nlm.nih.gov/pubmed/15477642 (åbner nyt vindue)

Pilot study on the safety and efficacy of desmopressin for the treatment or prevention of bleeding in patients with hematologic malignancies. (åbner nyt vindue)

Castaman G, Bona ED, Schiavotto C, Trentin L, D'Emilio A, Rodeghiero F.

Kilde‎: Haematologica 1997;82(5):584-7.

Indekseret‎: PubMed 9407726

https://www.ncbi.nlm.nih.gov/pubmed/9407726 (åbner nyt vindue)

Desmopressin and other synthetic vasopressin analogues in cancer treatment. (åbner nyt vindue)

Gomez DE, Ripoll GV, Girón S, Alonso DF.

Kilde‎: Bull Cancer 2006;93(2):E7-12.

Indekseret‎: PubMed 16517412

https://www.ncbi.nlm.nih.gov/pubmed/16517412 (åbner nyt vindue)